# Ultrafiltration Versus IV Diuretics in Worsening Heart Failure

Study · id `cardio:ct-nct05318105` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05318105](<https://clinicaltrials.gov/study/NCT05318105>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05318105

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 167 participants.

## Technical summary

Registry record NCT05318105. Randomized; no masking; primary purpose treatment. Start 2022-06-28 (actual); primary completion 2025-10-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 167 participants (enrolled count; ClinicalTrials.gov record NCT05318105, source copy `cardio:ctgov-nct05318105-2026-06-25`, retrieved 2026-10-26)
- Started: 2022-06-28 (actual) (ClinicalTrials.gov record NCT05318105, source copy `cardio:ctgov-nct05318105-2026-06-25`, retrieved 2026-10-26)
- Primary completion: 2025-10-06 (actual) (ClinicalTrials.gov record NCT05318105, source copy `cardio:ctgov-nct05318105-2026-06-25`, retrieved 2026-10-26)
- Completion: 2026-04-07 (actual) (ClinicalTrials.gov record NCT05318105, source copy `cardio:ctgov-nct05318105-2026-06-25`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05318105, source copy `cardio:ctgov-nct05318105-2026-06-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05318105-2026-06-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
- Acronym: REVERSE-HF
- Condition: Heart Failure (for Example, Fluid Overload)
- Condition: Heart Failure
- Condition: Fluid Overload
- Intervention (Device): Aquadex Smartflow® System
- Intervention (Drug): IV Loop Diuretics
- Lead sponsor: Nuwellis, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: 1f21c9da361ec435c988de015e356a69ef9586b6a556abcd84c09700739bc322
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
